Abstract:Introduction: The role of matrix metalloproteinase 9 (MMP-9) and cellular fibronectin (c-Fn) in acute ischemic stroke is controversial. We systematically reviewed the literature to investigate the association of circulating MMP-9 and c-Fn levels and MMP-9 rs3918242 polymorphism with the risk of three outcome measures after stroke. Methods: We searched English and Chinese databases to identify eligible studies. Outcomes included severe brain edema, hemorrhagic transformation, and poor outcome (modified Rankin scale score ≥3). We estimated standardized mean differences (SMDs) and pooled odds ratios (ORs) with 95% confidence intervals (CIs). Results: Totally, 28 studies involving 7,239 patients were included in the analysis of circulating MMP-9 and c-Fn levels. Meta-analysis indicated higher levels of MMP-9 in patients with severe brain edema (SMD, 0.76; 95% CI, 0.18–1.35; four studies, 419 patients) and hemorrhagic transformation (SMD, 1.00; 95% CI, 0.41–1.59; 11 studies, 1,709 patients) but not poor outcome (SMD, 0.30; 95% CI, −0.12 to 0.72; four studies, 759 patients). Circulating c-Fn levels were also significantly higher in patients with severe brain edema (SMD, 1.55; 95% CI, 1.18–1.93; four studies, 419 patients), hemorrhagic transformation (SMD, 1.75; 95% CI, 0.72–2.78; four studies, 458 patients), and poor outcome (SMD, 0.46; 95% CI, 0.16–0.76; two studies, 210 patients). Meta-analysis of three studies indicated that the MMP-9 rs3918242 polymorphism may be associated with hemorrhagic transformation susceptibility under the dominant model (TT + CT vs. CC: OR, 0.621; 95% CI, 0.424–0.908; P = 0.014). No studies reported the association between MMP-9 rs3918242 polymorphism and brain edema or functional outcome after acute stroke. Conclusion: Our meta-analysis showed that higher MMP-9 levels were seen in stroke patients with severe brain edema and hemorrhagic transformation but not poor outcome. Circulating c-Fn levels appear to be associated with all three outcomes including severe brain edema, hemorrhagic transformation, and poor functional outcome. The C-to-T transition at the MMP-9 rs3918242 gene appears to reduce the risk of hemorrhagic transformation.

Association Between Serum Matrix Metalloproteinase-9 and Poor Prognosis in Acute Ischemic Stroke Patients: the Role of Dyslipidemia

Serum Matrix Metalloproteinase-9 Levels and Prognosis of Acute Ischemic Stroke.

Serum Matrix Metalloproteinase-9 is Associated with Depression after Acute Ischemic Stroke

Association of Matrix Metalloproteinase 9 and Cellular Fibronectin and Outcome in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis

Association Between Serum Hepatocyte Growth Factor and Prognosis of Ischemic Stroke: the Role of Blood Lipid Status

Serum Matrix Metalloproteinase-9 And Cognitive Impairment After Acute Ischemic Stroke

Predictive Value of Longitudinal Changes of Serum Matrix Metalloproteinase-9 and Brain-Derived Neurotrophic Factor in Acute Ischemic Stroke.

Abstract P237: Matrix Metalloproteinases (MMPs) And Risk Of Incident Hemorrhagic And Ischemic Stroke: The Atherosclerosis Risk In Communities Study (ARIC)

Stroke Prognosis: the Impact of Combined Thrombotic, Lipid, and Inflammatory Markers

Carotid Atherosclerosis and Matrix Metalloproteinase-9,and Lipoprotein(a) in Hypertensive Patients Complicated with Diabetes Mellitus

Abstract Tu010: Matrix Metallopeptidase 9 Contributes to the Beginning of Plaque and is a Potential Biomarker for the Early Identification of Atherosclerosis in Asymptomatic Patients with Diabetes

Is Matrix Metalloproteinase-9 Associated with Post-Stroke Cognitive Impairment or Dementia?

Prognostic Metrics Associated with Inflammation and Atherosclerosis Signaling Evaluate the Burden of Adverse Clinical Outcomes in Ischemic Stroke Patients.

Exploring the Role of MMP-9 and MMP-9/TIMP-1 Ratio in Subacute Stroke Recovery: A Prospective Observational Study

Matrix metallopeptidase 9 contributes to the beginning of plaque and is a potential biomarker for the early identification of atherosclerosis in asymptomatic patients with diabetes

Association of MMP9 with adverse features of plaque progression and residual inflammatory risk in patients with chronic coronary syndrome (CCS)

Correlation of LP-PLA2 and MMP-9 with the occurrence of early neurological deterioration in patients with acute ischemic stroke

Tissue inhibitor metalloproteinase-1 and clinical outcomes after acute ischemic stroke.

The Association of Systemic Inflammatory Response Index and Neutrophil-to-High-Density Lipoprotein Ratio Mediated by Fasting Blood Glucose with 90-Day Prognosis in Acute Ischemic Stroke Patients

The Change and Clinic Significance of MMP-9 and TIMP-1 in Acute Ischemic Stroke

Correction: Association of Dimethylarginines and Mediators of Inflammation after Acute Ischemic Stroke